News
LMAT
111.65
-2.75%
-3.16
Q1 2026 In Review - March Dividend Income Report
Seeking Alpha · 10h ago
LeMaitre Vascular to report first-quarter earnings after market close
PUBT · 2d ago
LeMaitre Vascular publishes 2025 annual report on Form 10-K
PUBT · 2d ago
LeMaitre Will Announce First Quarter 2026 Earnings Results on May 5, 2026
Barchart · 2d ago
LeMaitre Vascular announces annual shareholder meeting
PUBT · 2d ago
LeMaitre Vascular Announces Board Changes and Size Reduction
TipRanks · 2d ago
LeMaitre Vascular director Bridget Ross to step down, not seek re-election
PUBT · 2d ago
Weekly Report: what happened at LMAT last week (0406-0410)?
Weekly Report · 3d ago
Mid-cap healthcare stocks with A grade EPS revisions ahead of earnings
Seeking Alpha · 6d ago
LMAT Crosses Above Average Analyst Target
NASDAQ · 04/08 13:38
LeMaitre Vascular management presents at Needham Virtual Healthcare Conference
Reuters · 04/07 18:44
LeMaitre to Present at the 25th Annual Needham Virtual Healthcare Conference
Barchart · 04/07 13:39
3 Russell 2000 Stocks We Steer Clear Of
Barchart · 04/07 01:34
Weekly Report: what happened at LMAT last week (0330-0403)?
Weekly Report · 04/06 09:08
LeMaitre initiated with a Hold at Freedom Capital
TipRanks · 03/31 20:39
Weekly Report: what happened at LMAT last week (0323-0327)?
Weekly Report · 03/30 09:08
Artivion, Intuitive Surgical, GE HealthCare, LeMaitre, and Globus Medical Shares Plummet, What You Need To Know
Barchart · 03/27 13:16
Weekly Report: what happened at LMAT last week (0316-0320)?
Weekly Report · 03/23 09:08
The Two Forces Reshaping Your Portfolio - February Dividend Income Report
Seeking Alpha · 03/21 03:45
Weekly Report: what happened at LMAT last week (0309-0313)?
Weekly Report · 03/16 09:08
More
Webull provides a variety of real-time LMAT stock news. You can receive the latest news about Lemaitre Vasculr through multiple platforms. This information may help you make smarter investment decisions.
About LMAT
LeMaitre Vascular, Inc. is a provider of devices, implants, and services for the treatment of peripheral vascular disease. The Company develops, manufactures, and markets vascular devices to address the needs of vascular surgeons and other specialties, such as cardiac surgeons, general surgeons, and neurosurgeons. Its portfolio of product lines is used to treat vascular disease, which used in open vascular surgery and dialysis access. It also offers human vascular and cardiac tissue cryopreservation services. Its principal product lines include anastomotic clips, biologic vascular and dialysis grafts, biologic vascular and cardiac patches, carotid shunts, embolectomy and occlusion catheters, radiopaque marking tape, synthetic vascular and dialysis grafts, and valvulotomes. Its principal biologic offerings include vascular and cardiac patches as well as vascular and dialysis grafts. Its product offerings are sold primarily in the United States, Europe, Canada, and Asia Pacific.